Relationship between adipokines and periodontitis  by Furugen, Reiko et al.
Review article
Relationship between adipokines and periodontitis
Reiko Furugen, Hideaki Hayashida, Masayasu Kitamura, Toshiyuki Saito *
Department of Oral Health, Nagasaki University Graduate School of Biomedical sciences, 1-7-1 Sakamoto, Nagasaki 852-8588, Japan
Received 16 March 2009; received in revised form 28 December 2009; accepted 5 January 2010
Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
2. Relationship of adipokines with inflammation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
3. Adiponectin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
4. Leptin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161
5. Resistin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162
6. Adipocyte and innate immunity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162
7. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163
Acknowledgement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163
References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163









Summary Obesity is associated with an increased risk for developing characteristic features of
metabolic syndrome, including hypertension, type 2 diabetes, and dyslipidemia. Interestingly,
chronicexposure toperiodontalpathogens’endotoxinand increasedcytokineproductionhavebeen
proposed to enhance the risk for causing type 2 diabetes and cardiovascular complications. Obesity
has also recently been reported to be associated with periodontitis. Obesity induces macrophage
accumulation in adipose tissue, promotes chronic low-grade inflammation, and increases adipo-
kines derived from adipocytes. In this review, we summarize recent advances in understanding the
roles of adipokines in chronic inflammatory states such as periodontitis and focus primarily
on adiponectin, leptin, and resistin. Understanding the role of adipokines may help elucidate
relationships among periodontitis, obesity, type 2 diabetes, and cardiovascular diseases.
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Periodontitis is a chronic inflammatory state caused by per-
iodontopathic bacteria that evade immune defenses. In cases
of severe periodontitis, serum levels of interleukin-1 beta (IL-
1b), IL-6, and tumor necrosis factor-alpha (TNF-a) werel Science. Published by Elsevier Ireland. All rights reserved.
160 R. Furugen et al.shown to be elevated [1]. Periodontal inflammation can
activate monocytes in periodontal tissues, resulting in the
production of pro-inflammatory cytokines such as TNF-a and
IL-6 and the initiation of periodontal tissue destruction.
Increasing evidence suggests that chronic low-grade inflam-
mation, as occurs with periodontitis, plays an important role
in the pathogenesis of systemic diseases [2].
Metabolic syndrome is defined by an amalgam of obesity-
associated disorders, including dyslipidemia, hypertension,
hyperglycemia. Of these, visceral adiposity appears to be
essential for the diagnosis of metabolic syndrome; indeed,
visceral adiposity was shown to be more important in meta-
bolic syndrome than overall adiposity [3].
Periodontitis is closely associated with diabetes and obe-
sity [4,5], and individuals who were obese or had metabolic
syndrome were shown to be at risk for developing period-
ontitis [6,7]. Specifically, the relationship between obesity
and deep periodontal pockets was independent of glucose
tolerance status, suggesting a direct association between
obesity and periodontitis [8]. Body mass index (BMI; calcu-
lated as weight in kilograms divided by the square of height in
meters) was positively correlated with periodontal attach-
ment loss [9]. Nevertheless, the biological mechanisms that
relate obesity with periodontitis are unclear.
Adipose tissue participates in the regulation of energy
homeostasis and is an active endocrine organ that secretes
more than 50 biologically active substances, collectively
termed adipokines. Adipokines such as the hormone-like
proteins: leptin and adiponectin, the classical pro-inflamma-
tory cytokines: TNF-a and IL-6, and plasminogen activator
inhibitor 1 (PAI-1) play a number of different biological roles
(Fig. 1) [10], acting in both paracrine and endocrine fashions.
Some of these cytokines appear to be key regulators of the
inflammatory response and are crucial for the progression of
periodontitis. T cells that secrete such cytokines have an
important function in periodontal inflammation. For exam-
ple, T helper (Th) cells were shown to be associated with
bone resorption by periodontopathic bacteria. Th cells are
divided into two functional subsets on the basis of cytokine
secretion; Th1 secretes IL-2, IL-12, and interferon-g, and Th2
secretes IL-4, IL-5, and IL-13. Diseased periodontal tissues
initially show predominance of Th1-type cytokines, followed
by a rise in Th2-type cytokines in later stages of periodontitis
[11]. Recent studies have also defined novel roles for Th17Figure 1 Adipokines are bioactive substances that are secret-
ed from adipose tissue. Adipose tissue is the main energy store in
the body and is also a source of paracrine and endocrine factors
that modulate the inflammatory response, vascular function,
and insulin sensitivity.cells, which secrete IL-17, TNF-a, and granulocyte colony
stimulating factor (G-CSF) [12]. In this review, we discuss the
relationship of adipokines and cytokines with periodontal
inflammation. There are many signs that regarding the asso-
ciations between periodontitis and each adipokines [12—18]
(Table 1).
2. Relationship of adipokines with
inflammation
Adipose tissues contain preadipocytes, endothelial cells,
leukocytes, and macrophages. The numbers of macrophages
in or near adipose tissues are small in lean subjects. In obese
mice and humans, however, macrophages are increased in
abundance and accumulate near adipocytes [19,20]. Macro-
phages in adipose tissues may increase the production of
inflammatory cytokines such as TNF-a and IL-6 that contri-
bute to obesity-related systemic disease (Fig. 2) [21]. The
close relationship between adipocyte size and macrophage
abundance in adipose tissues suggests that obesity promotes
inflammation [22]. Similarly, pro-inflammatory cytokines
such as IL-6 are induced to a greater extent in co-culture
systems after stimulation with lipopolysaccharide (LPS) from
Escherichia coli, which is thought to promote the develop-
ment of type 2 diabetes and vascular complications [23].
Macrophages in adipose tissues can secrete different
panels of cytokines. Analogous to the Th1/Th2 concept,
these macrophages are classified into M1 and M2 macro-
phages based on their cytokine generation. M1 macrophages
are suspected to be the major source of IL-1, IL-6, and TNF-a
[24]. It is thought that increased circulating TNF-a plays an
important role in insulin resistance, and increased circulating
IL-6 has been associated with an increased risk for cardio-
vascular disease. M2 macrophages have been reported to be
induced primarily by IL-4 and IL-13 and are capable of
producing anti-inflammatory compounds. Obesity causes an
M2 to M1 shift in adipose tissue macrophages.
3. Adiponectin
Adiponectin is a 30-kDa polypeptide that is specifically and
highly expressed in human adipose tissues [25]. This protein
has been shown to enhance insulin sensitivity and reduce
circulating fatty acids and triglycerides in muscle and liver
[26]. Adiponectin was first cloned from mice [27] and was
subsequently cloned from humans [25]; human adiponectin
shares 83% amino acid identity with mouse adiponectin [28].
The circulating level of adiponectin is relatively high (5—
10 mg/mL). Serum adiponectin levels are decreased in obese
humans and in patients with type 2 diabetes [29]; hence, the
adiponectin level tends to reflect insulin sensitivity. Adipo-
nectin circulates in the blood in trimeric (low molecular
weight, LMW), hexameric (medium molecular weight,
MMW), and multimeric (high molecular weight, HMW) forms
[30]. Among these forms, HMW adiponectin was shown to be
decreased in obesity and diabetes [31] and is associated with
an increased risk for the development of diabetes, indepen-
dent of total adiponectin [32]. Recent studies suggested that
the ratio of HMW to total adiponectin or to LMW (and not
the absolute amount of adiponectin) in peripheral blood
reflects insulin sensitivity [33]. The adiponectin isoforms
Table 1 Summerized the relationship between adipokines and periodontitis.
Authors and year Study design Major result
Kamio et al.
2009 [12]
In vitro study Globular adiponectin has an anti-inflammatory activity in periodontitis.
Furugen et al.
2008 [13]
Cross-sectional study Increased surum resistin is associated with periodontal condition
considering bleeding on probing.
Saito et al.
2008 [14]




Cross-sectional study Leptin levels decreased progressively in gingival crevicular fluid from
healthy gingiva to periodontitis and increased in serum with periodontitis.
Yamaguchi et al.
2007 [17]




Clinical study Periodontal treatment is effective in reducing TNF-a, and adiponectin is
not influenced.
Adipokines and periodontitis 161have different effects on human monocytes [34]. HMW adi-
ponectin induced IL-6 in human monocytes but did not sup-
press IL-6 secretion induced by LPS. Moreover, the globular
form of adiponectin (gAd), which is generated from full-
length adiponectin with proteolytic cleavage by elastase
secreted from activated macrophages and/or neutrophils,
is a powerful inducer of TNF-a and IL-6 secretion in primary
human peripheral macrophages. However, pre-exposure of
macrophages to gAd induced NF-kB activation and tolerance
to further gAd and LPS exposure, resulting in the repression
of TNF-a and IL-6 secretion [35].
We reported that periodontal conditions did not relate to
decreased adiponectin levels [13,14], and an antimicrobial
periodontal treatment did not increase adiponectin levels
[18]. HMW adiponectin but not LMW is induced a dose-
dependent increase in production of IL-8 and MCP-1 in human
peripheral blood mononuclear cell, in vitro [36]. This sug-
gested that HMWadiponectin is proinflammmatory. The rela-
tionships of HMW adiponectin with periodontal inflammation
should be examined, since the ratio of the high molecularFigure 2 Adipocyte-macrophage interactions. Lean adipose
tissue is composed of small adipocytes containing few macro-
phages, whereas large adipocytes in the obese state are associ-
ated withmoremacrophages. Lean adipose tissue secretes a high
level of adiponectin and low levels of leptin and resistin. Con-
versely, in obese adipose tissues, the adiponectin level is low,
and resistin levels are high.weight of adiponectin to that of total may be a better
predictor of periodontal inflammation.
Adipose TNF-a mRNA expression was elevated in obese
mice and humans [37], and the administration of adiponectin
suppressed TNF-a mRNA expression in local tissues and
decreased circulating levels of TNF-a. The anti-inflammatory
properties of adiponectin appear to antagonize the effects of
TNF-a [38]. This may be related to the structural resem-
blance between the cytokines, despite the lack of similarity
between their primary sequences.
Adiponectin has been shown to inhibit monocyte adhe-
sion to endothelial cells and macrophage transformation to
foam cells [39]. It also appears to be important in bacterial
and viral infections. It was shown to negatively regulate
mouse macrophage-like cell responses to Toll-like receptor
(TLR) ligands [40]. Furthermore, it acted as an inhibitor of
osteoclast formation stimulated by LPS from periodonto-
pathic bacteria [17]. Collectively, these observations sug-
gest that adiponectin may inhibit alveolar bone loss in
periodontitis.
4. Leptin
Leptin is a 16-kDa non-glycosylated peptide hormone
encoded by the ob gene and was initially thought to regulate
body weight by inhibiting food intake and by stimulating
energy expenditure. Mice with a mutated ob gene developed
severe obesity related to the lack of signaling in the brain-gut
axis. Leptin in humans is positively correlated with body fat
mass and is decreased upon weight reduction [41]. For
example, insulin has been shown to stimulate leptin secre-
tion during feeding, and starvation, to decrease leptin secre-
tion in humans [42]. Leptin is a known regulator of energy
homeostasis and modulates the inflammatory response and
immune system [43].
The role of leptin in the immune response has been a
subject of recent interest. It was shown that leptin synthesis
is increased by a number of inflammatory stimuli, including
IL-1, IL-6, TNF-a, and LPS [44]. An increase in leptin secretion
during infection and inflammation strongly suggests that it is
involved in the cytokine network that governs host defense
mechanisms. Leptin receptors are known to be expressed in
adipocytes, T lymphocytes, and vascular endothelial cells.
Table 2 Serum resistin and adiponectin levels in the subjects with periodontal conditions and control subjects [13,14].
Periodontal status n Resistin (ng/mL) p Adiponectin (mg/mL) p
Niigata study [13]a
Control 74 4.9  0.4b 0.138 12.0  0.6b 0.248
Periodontitis 84 5.6  0.3 11.0  0.6
Niigata study [13]a
Control without bleeding 60 4.8  0.4 0.037 11.7  0.8 0.551
Periodontitis with bleeding 47 6.1  0.5 11.1  0.9
Hisayama study [14] c
Healthy gingival 42 8.0  5.2d 0.037 12.4  5.1 0.46
Periodontitis 34 9.9  5.0 11.5  5.0
a ANCOVA was performed adjusting for sex, BMI, fasting glucose, and smoking.
b Data are expressed as the mean  standard error of mean.
c Mann—Whitney U-test.
d Data are expressed as the mean  standard deviation.
162 R. Furugen et al.Karthikeyan and Pradeep reported that leptin concentra-
tions in gingival crevicular fluid (GCF) were found to be higher
in healthy gingiva than in tissues with periodontitis [15].
Conversely, serum leptin levels are increased in people with
periodontitis [16]. The mechanism of these discrepancies
between GCF and serum leptin levels with/without period-
ontitis remains unclear. One possible explanation is specu-
lated that the secreted leptin may be used up as a substrate
during inflammation. Furthermore, the levels of leptin in GCF
were demonstrated to be significantly lower in smokers than
in non-smokers [45].
Leptin may exacerbate auto-immune reactions such as
type 1 diabetes and rheumatoid arthritis. It may reduce T
regulatory cells, which constitute 5—10% of CD4+ T cells.
Considering that in the initial and stable stages of periodontal
inflammation, Th1 is the dominant cell type, leptin might
contribute to periodontal inflammation concerning to T cell
immune reactions.
5. Resistin
Resistin is a 12.5-kDa polypeptide hormone that was first
identified as a gene responsive to antidiabetic drugs known as
thiazolidinediones. It belongs to the found in the inflamma-
tory zones (FIZZ) family, and FIZZ3/resistin is linked to
obesity and diabetes. The administration of recombinant
resistin decreased insulin responsiveness in mice and in an
adipocyte cell line [46]. Resistin is expressed abundantly in
adipose tissues of mice; however, in humans, resistin is
expressed at very low levels in adipocytes, whereas at higher
levels in circulating blood monocytes, mononuclear leuko-
cytes, and macrophages [47]. The genes for human resistin
andmouse resistin are located on different chromosomes and
have an amino acid identity of only 60% [46].
Circulating resistin levels are elevated in patients with
cardiovascular disease [48]. The effect of resistin on inflam-
mation was shown to be related to the expression of vascular
adhesion molecules. Human resistin acts as a pro-inflamma-
tory molecule and stimulates the synthesis and secretion of
TNF-a and IL-12 [49]. LPS was shown to increase resistin
mRNA levels in mouse adipocytes and human peripheral
blood monocytes. In addition to TNF-a and IL-6, resistinmay participate in inflammatory processes caused by bacter-
ial infections [50].
We reported that periodontitis was significantly asso-
ciated with increased levels of resistin, after adjustment
for gender, smoking, fasting glucose, and BMI. This associa-
tion was promoted under bleeding conditions of the period-
ontium (Table 2) [13,14]. Other inflammatory cytokines such
as IL-6, TNF-a and IL-1b have an effect on the expression of
resistin in vitro, suggesting that chronic periodontal inflam-
mation may influence resistin expression. Furthermore, the
administration of E. coli LPS in humans is associated with
increased circulating resistin levels [51]. LPS originated from
periodontal pathogens may influences adipose tissues and
macrophages through inflammatory cytokines as described
above. Moreover, a potential role for resistin in bone meta-
bolism was suggested by increased resistin levels that coin-
cided with osteoclast differentiation [52]. The physiological
functions of resistin during periodontal inflammation remain
unclear and warrant further investigation.
6. Adipocyte and innate immunity
TLRs have emerged as a first line of defense against infec-
tious diseases caused by bacteria. TLRs were shown to be
critical for efficient innate and adaptive immunity. For
example, TLR2 recognizes peptidoglycans found in Gram-
positive bacteria, and TLR4 recognizes LPS. TLRs have been
detected on many types of cells, including macrophages, T
cells, and epithelial cells. Reportedly, leptin can induce TLR
expression and responsiveness in both preadipocytes and
mature adipocytes, which suggests that leptin immunomo-
dulates adipocyte function and that adipocytes contribute
to the innate immune system [53]. Also, adiponectin acts as a
negative regulator of the inflammatory response induced by
TLR inmacrophage-like cells [40]. Nutritional fatty acids can
affect TLR4 signaling inmonocytes and adipocytes [54]. Mice
lacking TLR4 are protected against insulin resistance
induced by a high-fat diet. TLR4 in adipocytes that is acti-
vated by either LPS or free fatty acids enhances the expres-
sion of TNF-a and IL-6, which leads to systemic insulin
resistance [55]. TLR4 is likely activated chronically in the
obese state and could play an important role in metabolic
Figure 3 The relationship among periodontitis and adipokines.
Adipokines and periodontitis 163syndrome. TLRs were promoting inflammatory changes
in adipocyte-macrophage co-culture systems [56]. LPS
from Aggregatibacter actinomycetemcomitans, which is
associated with progressive periodontitis, is recognized
by TLR4 [40]. TLR4 activation in both adipocytes and
macrophages regulates the production of various cytokines
and therefore may be associated with periodontal inflam-
mation.
7. Conclusions
TNF-a and IL-6 increased by the progression to severe forms
of periodontitis may affect glucose metabolism. Hence, the
elevation of these cytokines attributable to periodontitis
could increase the risk for insulin resistance (Fig. 3). As
low-grade inflammation is involved in the pathogenesis of
systemic diseases such as type 2 diabetes, the dysregulation
of cytokine secretion by adipose tissues or macrophages may
be critical in disease pathogenesis. Decreases in the levels of
C-reactive protein and TNF-a following antimicrobial period-
ontal treatment may effectively reduce the risk for coronary
heart disease [18]. In addition to a Porphyromonas gingivalis
LPS challenge, diet-induced obesity may also increase the
risk for developing bacterial infections [57].
Although epidemiological studies concerned with adipo-
kines and periodontitis were performed in cross-sectional
studies, the cause-effect relationship is not clarified at pre-
sent. Hereafter, prospective large cohort studies with adi-
pokines levels in subjects with periodontitis and
interventional studies by periodontal treatment, are needed
to clarify the relationship between adipokines and period-
ontitis.
Periodontal inflammation may affect systemic inflamma-
tory processes and immune function. Mechanistic insights
revealed with state-of-the-art approaches will be useful
for developing strategies to combat periodontal disease
and other pathologies characterized by inflammation.
Acknowledgement
This study was partially supported by a Grant-in-aid for
Scientific Research (B) 19390542 (T.S.) from the Ministry of
Education, Culture, Sports, Science and Technology of Japan.References
[1] Okada H, Murakami S. Cytokine expression in periodontal health
and disease. Crit Rev Oral Biol Med 1998;9:248—66.
[2] Southerland JH, Taylor GW, Moss K, Beck JD, Offenbacher S.
Commonality in chronic inflammatory diseases: periodontitis,
diabetes, and coronary artery disease. Periodontology 2006;
2000(40):130—43.
[3] Kopelman PG. Obesity as a medical problem. Nature
2000;404:635—43.
[4] Saito T, Shimazaki Y, Sakamoto M. Obesity and periodontitis. N
Engl J Med 1998;339:482—3.
[5] Pischon N, Heng N, Bernimoulin JP, Kleber BM, Willich SN,
Pischon T. Obesity, inflammation, and periodontal disease.
J Dent Res 2007;86:400—9.
[6] Saito T, Shimazaki Y. Metabolic disorders related to obesity and
periodontal disease. Periodontology 2007;2000(43):254—66.
[7] Shimazaki Y, Saito T, Yonemoto K, Kiyohara Y, Iida M, Yamashita Y.
Relationship of metabolic syndrome to periodontal disease in
Japanesewomen: theHisayamastudy. JDentRes2007;86:271—5.
[8] Saito T, Shimazaki Y, Kiyohara Y, Kato I, Kubo M, Iida M, et al.
Relationship between obesity, glucose tolerance, and periodon-
tal disease in Japanese women: the Hisayama study. J Periodon-
tal Res 2005;40:346—53.
[9] Genco RJ, Grossi SG, Ho A, Nishimura F, Murayama Y. A proposed
model linking inflammation to obesity, diabetes, and periodon-
tal infections. J Periodontol 2005;76:2075—84.
[10] Garlet GP, Cardoso CR, Silva TA, Ferreira BR, Avila-Campos MJ,
Cunha FQ, et al. Cytokine pattern determines the progression of
experimental periodontal disease induced by Actinobacillus
actinomycetemcomitans through the modulation of MMPs
RANKL, and their physiological inhibitors. Oral Microbiol Immu-
nol 2006;21:12—20.
[11] Gaffen SL, Hajishengallis G. A new inflammatory cytokine on the
block: re-thinking periodontal disease and the Th1/Th2 para-
digm in the context of Th17 cells and IL-17. J Dent Res
2008;87:817—28.
[12] Kamio N, Akifusa S, Yamaguchi N, Nonaka K, Yamashita Y. Anti-
inflammatory activity of a globular adiponectin function on RAW
264 cells stimulated by lipopolysaccharide from Aggregatibac-
ter actinomycetemcomitans. FEMS Immunol Med Microbiol
2009;56:241—7.
[13] Furugen R, Hayashida H, Yamaguchi N, Yoshihara A, Ogawa H,
Miyazaki H, et al. The relationship between periodontal condi-
tion and serum levels of resistin and adiponectin in elderly
Japanese. J Periodontal Res 2008;43:556—62.
[14] Saito T, Yamaguchi N, Shimazaki Y, Hayashida H, Yonemoto K, Doi
Y, et al. Serum levels of resistin and adiponectin in women with
periodontitis: the Hisayama study. J Dent Res 2008;87:319—22.
[15] Karthikeyan BV, Pradeep AR. Leptin levels in gingival crevicular
fluid in periodontal health and disease. J Periodontal Res
2007;42:300—4.
[16] Karthikeyan BV, Pradeep AR. Gingival crevicular fluid and serum
leptin: their relationship to periodontal health and disease.
J Clin Periodontol 2007;34:467—72.
[17] Yamaguchi N, Kukita T, Li YJ, Martinez Argueta JG, Saito T,
Hanazawa S, et al. Adiponectin inhibits osteoclast formation
stimulated by lipopolysaccharide from Actinobacillus actino-
mycetemcomitans. FEMS Immunol Med Microbiol 2007;49:
28—34.
[18] Iwamoto Y, Nishimura F, Soga Y, Takeuchi K, Kurihara M, Taka-
shiba S, et al. Antimicrobial periodontal treatment decreases
serum C-reactive protein, tumor necrosis factor-alpha, but not
adiponectin levels in patients with chronic periodontitis.
J Periodontol 2003;74:1231—6.
[19] Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL,
Ferrante Jr AW. Obesity is associated with macrophage accu-
mulation in adipose tissue. J Clin Invest 2003;112:1796—808.
164 R. Furugen et al.[20] Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic
inflammation in fat plays a crucial role in the development of
obesity-related insulin resistance. J Clin Invest 2003;112:
1821—30.
[21] Cancello R, Tordjman J, Poitou C, Guilhem G, Bouillot JL, Hugol
D, et al. Increased infiltration of macrophages in omental
adipose tissue is associated with marked hepatic lesions in
morbid human obesity. Diabetes 2006;55:1554—61.
[22] Suganami T, Nishida J, Ogawa Y. A paracrine loop between
adipocytes and macrophages aggravates inflammatory changes:
role of free fatty acids and tumor necrosis factor alpha. Arter-
ioscler Thromb Vasc Biol 2005;25:2062—8.
[23] Yamashita A, Soga Y, Iwamoto Y, Yoshizawa S, Iwata H, Koke-
guchi S, et al. Macrophage-adipocyte interaction: marked in-
terleukin-6 production by lipopolysaccharide. Obesity (Silver
Spring) 2007;15:2549—52.
[24] Zeyda M, Stulnig TM. Adipose tissuemacrophages. Immunol Lett
2007;112:61—7.
[25] Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y,
Matsubara K. cDNA cloning and expression of a novel adipose
specific collagen-like factor, apM1 (adipose most abundant
gene transcript 1). Biochem Biophys Res Commun 1996;221:
286—9.
[26] Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K,
et al. The fat-derived hormone adiponectin reverses insulin
resistance associated with both lipoatrophy and obesity. Nat
Med 2001;7:941—6.
[27] Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel
serum protein similar to C1q, produced exclusively in adipo-
cytes. J Biol Chem 1995;270:26746—9.
[28] Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB.
Adiponectin–—a key adipokine in the metabolic syndrome. Dia-
betes Obes Metab 2006;8:264—80.
[29] Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto
Y, et al. Plasma concentrations of a novel, adipose-specific
protein, adiponectin, in type 2 diabetic patients. Arterioscler
Thromb Vasc Biol 2000;20:1595—9.
[30] Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, et al.
Impaired multimerization of human adiponectin mutants asso-
ciated with diabetes. Molecular structure and multimer forma-
tion of adiponectin. J Biol Chem 2003;278:40352—63.
[31] Scherer PE. Adipose tissue: from lipid storage compartment to
endocrine organ. Diabetes 2006;55:1537—45.
[32] Heidemann C, Sun Q, van Dam RM, Meigs JB, Zhang C, Tworoger
SS, et al. Total and high-molecular-weight adiponectin and
resistin in relation to the risk for type 2 diabetes in women.
Ann Intern Med 2008;149:307—16.
[33] Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger
JP, et al. Complex distribution, not absolute amount of adipo-
nectin, correlates with thiazolidinedione-mediated improve-
ment in insulin sensitivity. J Biol Chem 2004;279:12152—6.
[34] Neumeier M, Weigert J, Schaffler A, Wehrwein G, Muller-Ladner
U, Scholmerich J, et al. Different effects of adiponectin iso-
forms in human monocytic cells. J Leukoc Biol 2006;79:803—8.
[35] Tsatsanis C, Zacharioudaki V, Androulidaki A, Dermitzaki E,
Charalampopoulos I, Minas V, et al. Adiponectin induces TNF-
alpha and IL-6 in macrophages and promotes tolerance to itself
and other pro-inflammatory stimuli. Biochem Biophys Res Com-
mun 2005;335:1254—63.
[36] Song H, Chan J, Rovin BH. Induction of chemokine expression by
adiponectin in vitro is isoform dependent. Transl Res 2009;154:
18—26.
[37] Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM.
Increased adipose tissue expression of tumor necrosis factor-
alpha in human obesity and insulin resistance. J Clin Invest
1995;95:2409—15.
[38] Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G.
Adiponectin expression from human adipose tissue: relationto obesity, insulin resistance, and tumor necrosis factor-alpha
expression. Diabetes 2003;52:1779—85.
[39] Fasshauer M, Paschke R, Stumvoll M. Adiponectin, obesity, and
cardiovascular disease. Biochimie 2004;86:779—84.
[40] Yamaguchi N, Argueta JG, Masuhiro Y, Kagishita M, Nonaka K,
Saito T, et al. Adiponectin inhibits toll-like receptor family-
induced signaling. FEBS Lett 2005;579:6821—6.
[41] Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens
TW, Nyce MR, et al. Serum immunoreactive-leptin concentra-
tions in normal-weight and obese humans. N Engl J Med
1996;334:292—5.
[42] Segal KR, Landt M, Klein S. Relationship between insulin sensi-
tivity and plasma leptin concentration in lean and obese men.
Diabetes 1996;45:988—91.
[43] Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman
JM. Positional cloning of the mouse obese gene and its human
homologue. Nature 1994;372:425—32.
[44] Sarraf P, Frederich RC, Turner EM, Ma G, Jaskowiak NT, Rivet DJ,
et al. Multiple cytokines and acute inflammation raise mouse
leptin levels: potential role in inflammatory anorexia. J Exp Med
1997;185:171—5.
[45] Bozkurt FY, Yetkin Ay Z, Sutcu R, Delibas N, Demirel R. Gingival
crevicular fluid leptin levels in periodontitis patients with long-
term and heavy smoking. J Periodontol 2006;77:634—40.
[46] Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright
CM, et al. The hormone resistin links obesity to diabetes. Nature
2001;409:307—12.
[47] Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Con-
sidine RV, et al. Resistin/fizz3 expression in relation to obesity
and peroxisome proliferator-activated receptor-gamma action
in humans. Diabetes 2001;50:2199—202.
[48] Takeishi Y, Niizeki T, Arimoto T, Nozaki N, Hirono O, Nitobe J,
et al. Serum resistin is associated with high risk in patients with
congestive heart failure–—a novel link between metabolic sig-
nals and heart failure. Circ J 2007;71:460—4.
[49] Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehte-
sham NZ. Human resistin stimulates the pro-inflammatory cyto-
kines TNF-alpha and IL-12 in macrophages by NF-kB-dependent
pathway. Biochem Biophys Res Commun 2005;334:1092—101.
[50] Lu SC, Shieh WY, Chen CY, Hsu SC, Chen HL. Lipopolysaccharide
increases resistin gene expression in vivo and in vitro. FEBS Lett
2002;530:158—62.
[51] Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA.
An inflammatory cascade leading to hyperresistinemia in
humans. PLoS Med 2004;1:e45.
[52] Thommesen L, Stunes AK, Monjo M, Grosvik K, Tamburstuen MV,
Kjobli E, et al. Expression and regulation of resistin in osteo-
blasts and osteoclasts indicate a role in bone metabolism. J Cell
Biochem 2006;99:824—34.
[53] Batra A, Pietsch J, Fedke I, Glauben R, Okur B, Stroh T, et al.
Leptin-dependent toll-like receptor expression and responsive-
ness in preadipocytes and adipocytes. Am J Pathol 2007;170:
1931—41.
[54] Shi H, KokoevaMV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links
innate immunity and fatty acid-induced insulin resistance. J
Clin Invest 2006;116:3015—25.
[55] Song MJ, Kim KH, Yoon JM, Kim JB. Activation of Toll-like
receptor 4 is associated with insulin resistance in adipocytes.
Biochem Biophys Res Commun 2006;346:739—45.
[56] Suganami T, Tanimoto-Koyama K, Nishida J, Itoh M, Yuan X,
Mizunami S, et al. Role of the Toll-like receptor 4/NF-kB
pathway in saturated fatty acid-induced inflammmatory
changes in the interaction between adipocytes and macro-
phages. Arterioscler Thromb Vasc Biol 2007;27:84—91.
[57] Amar S, Zhou Q, Shaik-Dasthagirisaheb Y, Leeman S. Diet-in-
duced obesity in mice causes changes in immune responses and
bone loss manifested by bacterial chalLnge. Proc Natl Acad Sci
USA 2007;104:20466—71.
